Contact Supplier

Contact Supplier

To get in touch with TAmiRNA GmbH, simply fill out the form below.

    Subscribe to Supplier

    Subscribe to Supplier


    TAmiRNA to present miND® NextGen sequencing insights to RNA Leaders Europe Congress in Basel

    news-releasesTAmiRNA GmbH
    March 5th 2024

    Vienna, Austria: Biotech and diagnostic innovator TAmiRNA will again be a scientific contributor to an RNA Leaders meeting, at their Spring 2024 European Congress in Basel, Switzerland.

    TAmiRNA co-founder and CEO Dr Matthias Hackl will be a keynote speaker at the conference, highlighting the recent development of reliable miRNA safety biomarkers and their potential to indicate injury of the liver, kidneys, pancreas, blood vessels, and central nervous system for drug development purposes.

    Using spike-ins

    Dr. Hackl’s presentation ‘Discovery & Validation of MicroRNA Biomarkers of Clinical Drug-Induced Organ Injury’ on Day One of the Congress (March 13; 12:25 hrs.), will trace TAmiRNA’s recent discovery and validation of novel microRNA-based safety biomarkers.

    These were isolated using the company’s unique RNA-sequencing workflow based on its miND® NextGen development technology, with its panel of spike-ins enabling more rapid and precise absolute quantitation of RNAs in liquid biopsies.

    A step further

    Matthias Hackl commented: “I am very pleased to be addressing the RNA Leaders Europe Congress with a chance to update my presentation to the US Congress in Boston last September, where I reviewed how safety and tolerability of drug candidates and newly approved drugs remain key concerns in pharma R&D, often leading to black box warnings, and withdrawal of otherwise promising innovative medicines. I said then that new technologies were needed to identify biomarkers more precisely and that the miND platform seemed to promise a solution.

    “Now I will be able to show how we have taken significant steps forward in applying the NextGen sequencing to overcome some of those safety concerns and identify microRNA biomarkers that form reliable diagnostic tools,” Dr. Hackl added.

    About TAmiRNA

    TAmiRNA specializes in technologies for profiling levels of blood-circulating miRNAs and developing multi-parametric classification algorithms (“signatures”). TAmiRNA uses these technologies to develop minimal-invasive diagnostic tests for drug development, early diagnosis, and prognosis of disease, and as companion diagnostic tests to support treatment decisions. Through its CRO business, TAmiRNA enables clients from academic to private sectors to perform high-quality biomarker and drug discovery research.

    TAmiRNA is among Europe´s first companies that have CE-marked a microRNA-based test – hepatomiR® – which is intended for the diagnosis of liver function in liver cancer patients.

    For its work on circulating microRNAs in bone disease, TAmiRNA is receiving funding from the European Union’s Horizon 2020 research and innovation program under the MARIE SKŁODOWSKA-CURIE grant agreement no. 860898. For TAmiRNA´s work on novel drug safety biomarkers, TAmiRNA receives funding from the Innovative Medicines Initiative 2 Joint Undertaking “TransBioLine” under grant agreement No. 821283. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. For its work on senescence-associated biomarkers, TAmiRNA is receiving funding from Eureka-Eurostars grant Ab-SENS. For its work on novel liver function biomarkers, TAmiRNA is receiving funding from the Vienna Business Agency as well as FFG.

    More information available at:

    About RNA Leaders Europe Congress 2024

    The RNA Leaders USA Congress is an event first hosted in 2022 by the LSX network for life science executives and dedicated to sharing knowledge concerning the rapidly expanding field of RNA-based therapeutics.

    Since then, it has developed a pattern of biannual meetings, with a Europe Congress Basel during the northern spring and a US Congress at Boston in the fall.

    The third Europe Congress is a two-day event opening March 13 at the Basel Congress Center. The conference will feature more than 120 speakers, covering a wide range of topics, including mRNA vaccine & therapeutics, Oligo-based RNA therapeutics, NextGen RNA modalities and applications, and novel delivery techniques. A Biotech Innovation Showcase will highlight RNA-based scientific advancements for new disease targets to address unmet medical needs, along with early-stage innovative technologies to tackle key challenges such as delivery, cell/tissue specificity and manufacturing cost reductions.

    The Europe Congress is organized by Informa Connect with further information at:


    Click on TAmiRNA miND® Next Generation Sequencing  for further information.


    hepatomiR® is a blood-based Biomaker for the Assessment of Live Function before Hepatectomy in patients with HCC, CCC or mCRC

    TAmiRNA to present miND® NextGen sequencing insights to RNA Leaders Europe Congress in Basel

    TAmiRNA CEO Dr. Matthias Hackl will be a Keynote Presenter at the RNA Leaders Europe Congress.

    TAmiRNA to present miND® NextGen sequencing insights to RNA Leaders Europe Congress in Basel

    miND® describes an oligonucleotide-based spike-in toolkit for quantifying biomarkers and an effective workflow for microRNA biomarker discovery.

    Contact TAmiRNA GmbH

    Simply fill out the form below to contact TAmiRNA GmbH now.

    Send TAmiRNA GmbH a Message